

CLAIMS

1. An adhesive, transdermal formulation containing a suspension of diclofenac sodium in polyoxyl hydrogenated castor oil, a cationic copolymer of a C₁-C₄ alkyl ester of methacrylic acid with an ester of methacrylic acid with a C₁-C₄ alcohol containing a secondary or tertiary amino group, one or more crosslinking agents for said copolymer, an adhesive system and, optionally, other excipients.
2. A formulation according to claim 1 wherein the crosslinking agents are chosen from polycarboxylic acids and long-chain acids.
3. A formulation according to claim 2 wherein the crosslinking agents are chosen from adipic acid, lauric acid, succinic acid.
4. A formulation according to any one of the previous claims, containing also acidifying/buffering agents, preservatives, flexibilizers.
5. A formulation according to claim 4 containing glycerin as a flexibilizer.
6. A formulation according to claim 4 containing citric acid as an acidifier.
7. A formulation according to any one of the previous claims, containing between 5 and 50% in weight of polyoxyl hydrogenated castor oil.
8. A formulation according to any one of the previous claims containing between 10 and 30% of polyoxyl hydrogenated castor oil.
9. A formulation according to any one of the previous claims, wherein the cationic copolymer is a copolymer based on dimethylamino ethylmethacrylate and neutral esters of methacrylic acid.
10. A formulation according to any one of the previous claims wherein the adhesive system is constituted by a copolymer of methacrylic acid with a C₁-C₄ ester of acrylic acid.
11. A transdermal patch constituted by a tissue on which a formulation

according to claims 1-10 is spread and by a protective layer.

12. A transdermal patch according to claim 11 wherein the tissue is 100% non-woven polyester and the protective layer is silicon paper.

13. A transdermal patch according to claim 11 or 12, containing 1 mg of
5 diclofenac sodium per cm^2 of patch.